Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019
Shots:
- The P-IIIb/IV SPIRIT-H2H study results involve assessing of Taltz vs Humira (adalimumab) in 566 patients with PsA who are biologic DMARD-naive for 52wks.
- The P-IIIb/IV SPIRIT-H2H study results: met its 1EPs & 2Eps i.e- @24wks. reduction by 50% in disease activity as defined by ACR50; PASI100 (36% vs 28%) & superior to Humira- ACR50 (51% vs 47%); PASI100 (60% vs 47%) respectively- will be presented at EULAR
- Taltz is a mAb targeting IL-17A cytokine- act by inhibiting its interaction with the IL-17 receptor which is involved in inflammatory and immune responses and inhibits the release of pro-inflammatory cytokines and chemokines
Ref: Eli Lilly | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com